On Mar. 8, 2021, ImmunityBio and NantKwest announced that the first cohorts of their South Africa and U.S. COVID-19 vaccine trials had received their initial doses of the companyﾒs T-cell-based COVID-19 vaccine candidate, hAd5.

This candidate was unique in targeting both the spike (S) and nucleocapsid (N) proteins of the SARS-CoV-2 virus.